2025
The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E
Ali M, Stockdale L, Sagara I, Zongo I, Yerbanga R, Mahamar A, Nikièma F, Tapily A, Sompougdou F, Diarra M, Bellamy D, Provstgaard-Morys S, Zoungrana C, Issiaka D, Haro A, Sanogo K, Sienou A, Kaya M, Traore S, Dicko O, Kone Y, Yalcouye H, Thera I, Diarra K, Snell P, Ofori-Anyinam O, Ockenhouse C, Lee C, Ewer K, Tinto H, Djimde A, Ouedraogo J, Dicko A, Chandramohan D, Greenwood B. The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E. Npj Vaccines 2025, 10: 26. PMID: 39915506, PMCID: PMC11802723, DOI: 10.1038/s41541-025-01078-0.Peer-Reviewed Original ResearchDoses of RTS,S/AS01RTS,S/AS01Dose of vaccineBooster dose of vaccineBooster doseAntibody responseCircumsporozoite proteinMalaria-endemic areas of AfricaRTS,S/AS01E malaria vaccineAnti-CSP antibody responsesAntibody titresBurden of malariaMalaria transmission seasonMalaria-endemic areasAnti-CSP antibodiesPlasmodium falciparum sporozoitesRisk of malariaMalaria vaccine RTS,S/AS01Incidence of malariaAssociated with protectionMultiplex assayYears of ageSevere malariaMalaria vaccineS/AS01
2024
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Datoo M, Dicko A, Tinto H, Ouédraogo J, Hamaluba M, Olotu A, Beaumont E, Lopez F, Natama H, Weston S, Chemba M, Compaore Y, Issiaka D, Salou D, Some A, Omenda S, Lawrie A, Bejon P, Rao H, Chandramohan D, Roberts R, Bharati S, Stockdale L, Gairola S, Greenwood B, Ewer K, Bradley J, Kulkarni P, Shaligram U, Hill A, Group R, Mahamar A, Sanogo K, Sidibe Y, Diarra K, Samassekou M, Attaher O, Tapily A, Diallo M, Dicko O, Kaya M, Maguiraga S, Sankare Y, Yalcouye H, Diarra S, Niambele S, Thera I, Sagara I, Sylla M, Dolo A, Misidai N, Simando S, Msami H, Juma O, Gutapaka N, Paul R, Mswata S, Sasamalo I, Johaness K, Sultan M, Alexander A, Kimaro I, Lwanga K, Mtungwe M, Khamis K, Rugarabam L, Kalinga W, Mohammed M, Kamange J, Msangi J, Mwaijande B, Mtaka I, Mhapa M, Mlaganile T, Mbaga T, Yerbanga R, Samtouma W, Sienou A, Kabre Z, Ouedraogo W, Yarbanga G, Zongo I, Savadogo H, Sanon J, Compaore J, Kere I, Yoni F, Sanre T, Ouattara S, Provstgaard-Morys S, Woods D, Snow R, Amek N, Ngetsa C, Ochola-Oyier L, Musyoki J, Munene M, Mumba N, Adetifa U, Muiruri C, Mwawaka J, Mwaganyuma M, Ndichu M, Weya J, Njogu K, Grant J, Webster J, Lakhkar A, Ido N, Traore O, Tahita M, Bonko M, Rouamba T, Ouedraogo D, Soma R, Millogo A, Ouedraogo E, Sorgho F, Konate F, Valea I. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. The Lancet 2024, 403: 533-544. PMID: 38310910, DOI: 10.1016/s0140-6736(23)02511-4.Peer-Reviewed Original ResearchConceptsClinical malaria episodesPhase 3 trialMalaria episodesMonths age groupAdverse eventsVaccine efficacyClinical malariaMalaria vaccineDouble-blindMalaria transmissionControl vaccineAsn-Ala-Asn-ProAge groupsStandard sitesMonths of follow-upAfrican childrenPerennial malaria transmissionBurden of malariaSeasonal malaria transmissionMalaria transmission intensityPhase 2b trialInjection site painFrequent adverse eventsCo-primary endpointsVaccine-induced antibodies
2020
Evaluation of seasonal malaria chemoprevention in two areas of intense seasonal malaria transmission: Secondary analysis of a household-randomised, placebo-controlled trial in Houndé District, Burkina Faso and Bougouni District, Mali
Cairns M, Sagara I, Zongo I, Kuepfer I, Thera I, Nikiema F, Diarra M, Yerbanga S, Barry A, Tapily A, Coumare S, Milligan P, Tinto H, Ouédraogo J, Chandramohan D, Greenwood B, Djimde A, Dicko A. Evaluation of seasonal malaria chemoprevention in two areas of intense seasonal malaria transmission: Secondary analysis of a household-randomised, placebo-controlled trial in Houndé District, Burkina Faso and Bougouni District, Mali. PLOS Medicine 2020, 17: e1003214. PMID: 32822362, PMCID: PMC7442230, DOI: 10.1371/journal.pmed.1003214.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionUncomplicated malariaTransmission seasonIntense seasonal malaria transmissionDay 28 PCRParasitological response rateUncomplicated clinical malariaPlacebo-controlled trialIncidence of hospitalisationSeasonal malaria transmissionIncidence rate ratiosBurden of malariaRapid diagnostic testsBougouni DistrictAsymptomatic malariaClinical malariaPlacebo groupStudy drugMalaria parasitaemiaAge range 3Parent trialAmodiaquine resistancePrevalence ratiosProtective efficacy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply